Seraxis, Inc.

It provides an environment for them to survive and thrive.

And then we know from the, uh, extensive data that, uh, Seraxis submitted to the FDA in order to be granted an IND approval in April of this year, we know that the cells work, we know that they are potent, and we know that they survive.

So the third leg of the stool, um, as we'll describe, is tackling immune suppression.

And not only are we gonna do that, uh, therapeutically, we also have a line of cells called SR03, which we believe-- which are gene-edited cells.